Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases.

Graham RP, Shrestha B, Caron BL, Smyrk TC, Grogg KL, Lloyd RV, Zhang L.

Am J Surg Pathol. 2013 Mar;37(3):399-405. doi: 10.1097/PAS.0b013e31826f042c.

PMID:
23348208
2.

Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.

Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A.

Am J Surg Pathol. 2008 Mar;32(3):420-5. doi: 10.1097/PAS.0b013e318158a397.

PMID:
18300808
3.

ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.

Agaimy A, Erlenbach-Wünsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, Kiesewetter F, Hartmann A, Zamboni G, Perren A, Klöppel G.

Mod Pathol. 2013 Jul;26(7):995-1003. doi: 10.1038/modpathol.2013.40. Epub 2013 Mar 15.

4.

Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.

Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D.

Mod Pathol. 2012 Jun;25(6):893-901. doi: 10.1038/modpathol.2012.34. Epub 2012 Mar 2.

5.

Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.

Hermann G, Konukiewitz B, Schmitt A, Perren A, Klöppel G.

Virchows Arch. 2011 Aug;459(2):147-54. doi: 10.1007/s00428-011-1118-6. Epub 2011 Jul 8.

PMID:
21739268
6.

Expression of the LIM homeobox domain transcription factor ISL1 (Islet-1) is frequent in rhabdomyosarcoma but very limited in other soft tissue sarcoma types.

Erlenbach-Wünsch K, Haller F, Taubert H, Würl P, Hartmann A, Agaimy A.

Pathology. 2014 Jun;46(4):289-95. doi: 10.1097/PAT.0000000000000091.

PMID:
24751901
7.

[Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].

Yao W, Wang W, Li G.

Zhonghua Zhong Liu Za Zhi. 2014 Apr;36(4):287-93. Chinese.

PMID:
24989916
8.

Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.

Delektorskaya VV, Kozlov NA, Chemeris GY.

Klin Lab Diagn. 2013 Oct;(10):48-50, 10-3. English, Russian.

PMID:
24640093
9.

NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.

Tseng IC, Yeh MM, Yang CY, Jeng YM.

Am J Surg Pathol. 2015 Jun;39(6):850-7. doi: 10.1097/PAS.0000000000000435.

PMID:
25871618
10.

Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.

Bishop JA, Sharma R, Illei PB.

Hum Pathol. 2010 Jan;41(1):20-5. doi: 10.1016/j.humpath.2009.06.014. Epub 2009 Sep 8.

PMID:
19740516
11.

The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.

Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL.

Mod Pathol. 2004 Nov;17(11):1392-9.

12.

The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms.

Schimmack S, Lawrence B, Svejda B, Alaimo D, Schmitz-Winnenthal H, Fischer L, Büchler MW, Kidd M, Modlin I.

Cancer. 2012 May 15;118(10):2763-75. doi: 10.1002/cncr.26592. Epub 2011 Oct 11.

13.

ISL1 promotes pancreatic islet cell proliferation.

Guo T, Wang W, Zhang H, Liu Y, Chen P, Ma K, Zhou C.

PLoS One. 2011;6(8):e22387. doi: 10.1371/journal.pone.0022387. Epub 2011 Aug 4.

14.

The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.

Modlin IM, Drozdov I, Kidd M.

PLoS One. 2013 May 15;8(5):e63364. doi: 10.1371/journal.pone.0063364. Print 2013.

15.

PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.

Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK.

Mod Pathol. 2011 Mar;24(3):412-24. doi: 10.1038/modpathol.2010.176. Epub 2010 Oct 1.

16.

Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms.

Lin O, Olgac S, Green I, Zakowski MF, Klimstra DS.

Am J Clin Pathol. 2003 Aug;120(2):209-16.

PMID:
12931551
17.

Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis.

Konukiewitz B, Enosawa T, Klöppel G.

Virchows Arch. 2011 Jan;458(1):47-53. doi: 10.1007/s00428-010-0985-6. Epub 2010 Oct 5.

PMID:
20922407
18.

'Neuroendocrine' middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation.

Agaimy A, Lell M, Schaller T, Märkl B, Hornung J.

Histopathology. 2015 Jan;66(2):182-91. doi: 10.1111/his.12447. Epub 2014 Nov 10.

PMID:
24766278
19.

The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.

Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D.

Endocr Pathol. 2013 Dec;24(4):184-90. doi: 10.1007/s12022-013-9264-9.

PMID:
24037217
20.

Secondary malignancy in patients with sporadic neuroendocrine neoplasia.

Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A, Kröpil F, Cupisti K, Knoefel WT.

Endocrine. 2013 Oct;44(2):510-6. doi: 10.1007/s12020-013-9911-4. Epub 2013 Mar 14.

PMID:
23494366

Supplemental Content

Support Center